- Home
- MTNB vs TIVC Comparison
MTNB vs TIVC Comparison
Compare MTNB & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | TIVC |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTNB | TIVC |
|---|---|---|
| Price | $0.62 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 294.9K | 260.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $0.75 |
| 52 Week High | $3.09 | $5.60 |
Technical Indicators
Market Signals| Indicator | MTNB | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 69.31 |
| Support Level | $0.55 | $0.79 |
| Resistance Level | $0.66 | $2.70 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 57.87 | 100.00 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.